Navigation Links
CT Angiography Highly Accurate: Multicenter Trials Show
Date:11/26/2007

CHICAGO, Nov. 26 /PRNewswire/ -- Computed tomography (CT) angiography is as accurate as an invasive angiogram in detecting coronary artery disease, according to the findings of the first two prospective multicenter 64-slice scanner trials presented today at the annual meeting of the Radiological Society of North America (RSNA).

"These two trials with comparable results clearly set the stage for the widespread adoption of and reimbursement for coronary artery CT examinations," said Gerald D. Dodd III, M.D., chair of the Department of Radiology at the University of Texas Health Science Center in San Antonio.

For the Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography (CORE-64) Trial, researchers at nine international centers studied 291 patients who were scheduled to undergo invasive coronary angiography for suspected or unknown coronary artery disease. The study found that 64-slice multidetector CT angiography was highly accurate in detecting blockages of greater than 50 percent, with a sensitivity of 85 percent and a specificity of 90 percent. The noninvasive exam was equal in accuracy to invasive angiography in its ability to identify patients to be referred for angioplasty or bypass surgery.

"Reliable assessment of the presence of coronary blockages and accurate prediction of coronary revascularizations are feasible with 64-slice CT coronary angiography," said presenter Marc Dewey, M.D., radiologist at Humboldt University Berlin, Charite, Germany. "Patients with low to intermediate risk of having coronary blockages are most likely to benefit from coronary CT angiography, since in those patients the necessity of invasive angiography is greatly reduced."

The Assessment by Coronary Computed Tomographic Angiography of Individuals UndeRgoing InvAsive Coronary AngiographY (ACCURACY) Trial compared 64-row coronary computed tomographic angiography (CCTA) to quantitative coronary angiography (QCA). The re
'/>"/>

SOURCE Radiological Society of North America
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Catheter angiography may be an unnecessary follow-up to CT angiography
2. CT angiography highly accurate, multicenter trials show
3. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
4. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
5. 18F-DG PET/CT can highly increase the detection of colorectal cancer
6. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
7. Medical University of South Carolina Leads Multicenter Study Evaluating Biliary Sphincter Disorder
8. Study Questions Dead-End Cancer Clinical Trials
9. Clinical trials present better alternatives for dialysis patients
10. IMPACT initiative looks to improve patient participation in clinical trials
11. Clinical Trials Directive still hampering academic medical research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 1Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 4Natural born divers and the molecular traces of evolution 9035 1Natural born divers and the molecular traces of evolution 9035 2Reading the brain without poking it 9033 1Reading the brain without poking it 9033 2Reading the brain without poking it 9033 3Reading the brain without poking it 9033 4Reading the brain without poking it 9033 5